Hmdb loader
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2006-05-22 14:17:30 UTC
Update Date2022-03-07 02:49:12 UTC
HMDB IDHMDB0001984
Secondary Accession Numbers
  • HMDB0015347
  • HMDB01984
  • HMDB15347
Metabolite Identification
Common NameFinasteride
DescriptionFinasteride is only found in individuals that have used or taken this drug. Finasteride is an androgen antagonist. It is an orally active testosterone 5-alpha-reductase inhibitor. Finasteride is one of the currently available pharmacologic treatment modalities with proven efficacy for treatment of androgenetic alopecia. The mechanism of action has not been fully determined, but finasteride has shown to decrease scalp DHT concentration to the levels found in hairy scalp, reduce serum DHT, increase hair regrowth, and slow hair loss. Androgenetic alopecia (AGA), or male pattern hair loss, affects approximately 50% of the male population. AGA is an androgen-related condition in genetically predisposed individuals. There is no treatment to completely reverse AGA in advanced stages, but with medical treatment (e.g. finasteride), the progression can be arrested and partly reversed in the majority of patients who have mild to moderate AGA. Finasteride is also used as a surgical alternative for treatment of benign prostatic hyperplasia (PubChem). The mechanism of action of finasteride is based on its preferential inhibition of type II 5alpha-reductase through the formation of a stable complex with the enzyme. Inhibition of type II 5alpha-reductase blocks the peripheral conversion of testosterone to DHT (resulting in significant decreases in serum and tissue DHT concentrations), minimal to moderate increase in serum testosterone concentrations, and substantial increases in prostatic testosterone concentrations. As DHT appears to be the principal androgen responsible for stimulation of prostatic growth, a decrease in DHT concentrations will result in a decrease in prostatic volume (approximately 20-30% after 6-24 months of continued therapy). Finasteride may increase the sensitivity of prostate specific antigen to detect prostate cancer. At present, finasteride remains the only intervention shown in long-term prospective phase III clinical trials to reduce the incidence of prostate cancer (PMID: 18044109 , 17543725 , 17414641 , 17415094 , 17394699 ).
Structure
Data?1582752221
Synonyms
ValueSource
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideChEBI
FinasteridaChEBI
FinasteridumChEBI
PropeciaKegg
ProscarKegg
(5a,17b)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideGenerator
(5Α,17β)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideGenerator
Chibro-proscarHMDB
FinastidHMDB
FinpeciaHMDB
ProstideHMDB
Chibro proscarHMDB
EucoprostHMDB
Merck brand 1 OF finasterideHMDB
Merck brand 2 OF finasterideHMDB
Cahill may roberts brand OF finasterideHMDB
Lipha brand OF finasterideHMDB
Merck frosst brand 1 OF finasterideHMDB
Frosst iberica brand OF finasterideHMDB
MSD Chibropharm brand OF finasterideHMDB
Merck sharp and dohme brand 1 OF finasterideHMDB
PropeshiaHMDB
MSD Brand OF finasterideHMDB
Merck frosst brand 2 OF finasterideHMDB
Merck sharp and dhome brand 2 OF finasterideHMDB
Chemical FormulaC23H36N2O2
Average Molecular Weight372.5441
Monoisotopic Molecular Weight372.277678406
IUPAC Name(1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
Traditional Name(1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
CAS Registry Number98319-26-7
SMILES
[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
InChI Identifier
InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1
InChI KeyDBEPLOCGEIEOCV-WSBQPABSSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • 20-hydroxysteroid
  • Androgen-skeleton
  • 3-hydroxysteroid
  • Hydroxysteroid
  • 4-azasteroid
  • Azasteroid
  • Cyclic carboximidic acid
  • Carboximidic acid
  • Carboximidic acid derivative
  • Azacycle
  • Organoheterocyclic compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organic 1,3-dipolar compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Ontology
Disposition

Biological location

Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting Point252 - 254 °CNot Available
Boiling Point576.61 °C. @ 760.00 mm Hg (est)The Good Scents Company Information System
Water Solubility0.002 g/LNot Available
LogP3.03HANSCH,C ET AL. (1995)
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+Not Available200.011http://allccs.zhulab.cn/database/detail?ID=AllCCS00001177
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.002 g/LALOGPS
logP3.53ALOGPS
logP3.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)14.53ChemAxon
pKa (Strongest Basic)0.33ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 ŲChemAxon
Rotatable Bond Count2ChemAxon
Refractivity108.2 m³·mol⁻¹ChemAxon
Polarizability43.96 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+188.25631661259
DarkChem[M-H]-183.4631661259
AllCCS[M+H]+194.19632859911
AllCCS[M-H]-196.91132859911
DeepCCS[M-2H]-225.90830932474
DeepCCS[M+Na]+201.130932474

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Finasteride[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C3796.9Standard polar33892256
Finasteride[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C2830.3Standard non polar33892256
Finasteride[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C3405.1Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Finasteride,1TMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C3182.3Semi standard non polar33892256
Finasteride,1TMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C3157.4Standard non polar33892256
Finasteride,1TMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C3696.8Standard polar33892256
Finasteride,1TMS,isomer #2CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C3033.8Semi standard non polar33892256
Finasteride,1TMS,isomer #2CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C3159.4Standard non polar33892256
Finasteride,1TMS,isomer #2CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C3511.9Standard polar33892256
Finasteride,2TMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C3041.4Semi standard non polar33892256
Finasteride,2TMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C3208.9Standard non polar33892256
Finasteride,2TMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C3500.7Standard polar33892256
Finasteride,1TBDMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C3412.9Semi standard non polar33892256
Finasteride,1TBDMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C3403.5Standard non polar33892256
Finasteride,1TBDMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C3797.9Standard polar33892256
Finasteride,1TBDMS,isomer #2CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C3232.4Semi standard non polar33892256
Finasteride,1TBDMS,isomer #2CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C3394.5Standard non polar33892256
Finasteride,1TBDMS,isomer #2CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C3617.4Standard polar33892256
Finasteride,2TBDMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C3494.3Semi standard non polar33892256
Finasteride,2TBDMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C3647.9Standard non polar33892256
Finasteride,2TBDMS,isomer #1CC(C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)[Si](C)(C)C(C)(C)C3655.1Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Finasteride GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a4i-1579000000-3a73a92e1d34b87c3e4c2017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Finasteride GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride LC-ESI-qTof , Positive-QTOFsplash10-0a4i-5910000000-7dd7b7fbb29b6ae08f4c2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOFsplash10-0ab9-1319000000-9f18f09bea4e9168f1df2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOFsplash10-0002-5900000000-3ad6a0d10c51f98921442017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOFsplash10-0a4i-0119000000-f683db304300c01e907a2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride LC-ESI-ITFT , positive-QTOFsplash10-0a4i-0129000000-a097bfd2187d4d4c97c62017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride , positive-QTOFsplash10-00xr-0119000000-43c6646bf19d622559662017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride , positive-QTOFsplash10-01b9-2539000000-c47506144391db372c4b2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride LC-ESI-QFT , positive-QTOFsplash10-014i-0900000000-a55cf309ee5a976c5e452017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 90V, Positive-QTOFsplash10-0aou-9400000000-e2d92afbb0c688a7c65f2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 50V, Positive-QTOFsplash10-0a4i-0936000000-473b441c435f8a167da52021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 40V, Positive-QTOFsplash10-05fr-0109000000-a6753fafb9b44a98b5ea2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 75V, Positive-QTOFsplash10-0aor-9500000000-2323be14f82809784cbb2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 15V, Positive-QTOFsplash10-00di-0009000000-5429921102770ed801ec2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 30V, Positive-QTOFsplash10-00di-0009000000-42255449abab8a1efb5b2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 30V, Positive-QTOFsplash10-00di-0009000000-5f84c9991fe026c301042021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 20V, Positive-QTOFsplash10-00di-0009000000-832f340612f54390180c2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 35V, Positive-QTOFsplash10-00di-0009000000-acfb1d6450dbdd3c37ce2021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 10V, Positive-QTOFsplash10-00di-0009000000-47e745329afb054081792021-09-20HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Finasteride 55V, Positive-QTOFsplash10-0ab9-0219000000-040ec285d4c909fdf0352021-09-20HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Finasteride 10V, Positive-QTOFsplash10-00di-0009000000-a6be7718311b4f11aad52016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Finasteride 20V, Positive-QTOFsplash10-0zmi-0439000000-e0a2fad4c18c6da72e1c2016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Finasteride 40V, Positive-QTOFsplash10-0uej-3790000000-df2f90aa3664e0df87762016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Finasteride 10V, Negative-QTOFsplash10-00di-0009000000-be3980c97e5b8f8767a62016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Finasteride 20V, Negative-QTOFsplash10-00di-3029000000-5489b391a47dec8eb0f12016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Finasteride 40V, Negative-QTOFsplash10-00dl-9131000000-a1b8897126899f67f5fb2016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Extracellular
  • Membrane
Biospecimen LocationsNot Available
Tissue LocationsNot Available
Pathways
Normal Concentrations
Not Available
Abnormal Concentrations
Not Available
Predicted Concentrations
BiospecimenValueOriginal ageOriginal sexOriginal conditionComments
Blood0.000 uMAdult (>18 years old)BothNormalPredicted based on drug qualities
Blood0.000 umol/mmol creatinineAdult (>18 years old)BothNormalPredicted based on drug qualities
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01216
Phenol Explorer Compound IDNot Available
FooDB IDFDB022782
KNApSAcK IDNot Available
Chemspider ID51714
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkFinasteride
METLIN IDNot Available
PubChem Compound57363
PDB IDNot Available
ChEBI ID5062
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDrw1561311
References
Synthesis ReferencePeng, Dongming; Huang, Kelong; Liu, Yanfei. Improved synthesis of finasteride. Zhongguo Yaowu Huaxue Zazhi (2005), 15(5), 288-290.
Material Safety Data Sheet (MSDS)Download (PDF)
General References
  1. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
  2. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y: Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25(2):208-13. [PubMed:20460827 ]
  3. Trueb RM: Pharmacologic interventions in aging hair. Clin Interv Aging. 2006;1(2):121-9. [PubMed:18044109 ]
  4. Otberg N, Finner AM, Shapiro J: Androgenetic alopecia. Endocrinol Metab Clin North Am. 2007 Jun;36(2):379-98. [PubMed:17543725 ]
  5. Lin AM, Small EJ: Prostate cancer update: 2006. Curr Opin Oncol. 2007 May;19(3):229-33. [PubMed:17414641 ]
  6. Dunn BK, Ford LG: Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prev. 2007 Jun;16(3):232-42. [PubMed:17415094 ]
  7. Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK: A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl. 2007 Apr;89(3):207-11. [PubMed:17394699 ]

Enzymes

General function:
Involved in 3-oxo-5-alpha-steroid 4-dehydrogenase activity
Specific function:
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene Name:
SRD5A1
Uniprot ID:
P18405
Molecular weight:
29458.18
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular weight:
57255.585
General function:
Involved in monooxygenase activity
Specific function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular weight:
55944.565
General function:
Involved in DNA binding
Specific function:
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3
Gene Name:
AR
Uniprot ID:
P10275
Molecular weight:
98987.9